AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17258718 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg/day
Number of subjects: 2587
Study 17258718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2587
Study 16385106 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapies in clinical trials
Number of subjects: 0
Study 16385106 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanism-based approach to treatment
Number of subjects: 0
Study 16385106 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 0
Study 16385106 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-trial testing of underlying pain mechanisms
Number of subjects: 0
Study 16385106 — intervention group
Group type: EXPERIMENTAL
Intervention: Study designs and potential solutions
Number of subjects: 0
Study 12236487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid at doses of 600, 1200, and 1800 mg/day
Number of subjects: 20
Study 12236487 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of ursodeoxycholic acid (not specified)
Number of subjects: 20
Study 9866083 — intervention group
Group type: EXPERIMENTAL
Intervention: GROUP‐CBT
Number of subjects: 60
Study 9866083 — intervention group
Group type: EXPERIMENTAL
Intervention: GROUP‐FAM
Number of subjects: 60
Study 9866083 — intervention group
Group type: COMPARATOR
Intervention: WL
Number of subjects: 60
Study 8582916 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical RGD peptide matrix
Number of subjects: 0
Study 8582916 — intervention group
Group type: COMPARATOR
Intervention: Control treatment with silver sulfadiazine
Number of subjects: 0
Study 2669473 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin GITS (Minipress XL) 10 mg
Number of subjects: 0
Study 2669473 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin GITS (Minipress XL) 20 mg
Number of subjects: 0
Study 2669473 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin GITS (Minipress XL) (10, 20 mg)
Number of subjects: 0
Study 2669473 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin GITS (Minipress XL)
Number of subjects: 0
Study 2669473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1175123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent courses of melphalan‐prednisone combinations
Number of subjects: 482
Study 29794310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical fusion surgery
Number of subjects: 49
Study 29794310 — intervention group
Group type: COMPARATOR
Intervention: Multimodal rehabilitation
Number of subjects: 49
Study 28625383 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchman left atrial appendage closure device
Number of subjects: 888
Study 28625383 — intervention group
Group type: COMPARATOR
Intervention: Single antiplatelet therapy or no therapy (control)
Number of subjects: 888
Study 26348661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Stress Management (CBSM)
Number of subjects: 74
Study 26348661 — intervention group
Group type: COMPARATOR
Intervention: Health Promotion (HP)
Number of subjects: 74
Study 24720242 — intervention group
Group type: EXPERIMENTAL
Intervention: Chaplain's offer of spiritual support
Number of subjects: 223
Study 24720242 — intervention group
Group type: COMPARATOR
Intervention: Nurse's offer of spiritual support
Number of subjects: 223
Study 20861404 — intervention group
Group type: EXPERIMENTAL
Intervention: Video film plus usual care
Number of subjects: 91
Study 20861404 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 91
Study 18475181 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 0
Study 18475181 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 0
Study 17296463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin ER 400 mg QD
Number of subjects: 40
Study 17296463 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin IR 200 mg BID
Number of subjects: 40
Study 17296463 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety assessment (vital signs, ECGs, adverse events)
Number of subjects: 40
Study 14732915 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic reviews of randomized trials in nephrology
Number of subjects: 0
Study 14732915 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 11333294 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g of alcohol per day
Number of subjects: 51
Study 11333294 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of alcohol per day
Number of subjects: 51
Study 11333294 — intervention group
Group type: COMPARATOR
Intervention: Placebo (alcohol-free beverage)
Number of subjects: 51
Study 9752963 — intervention group
Group type: EXPERIMENTAL
Intervention: Canal wall down tympanomastoidectomy
Number of subjects: 12
Study 9752963 — intervention group
Group type: COMPARATOR
Intervention: Intact canal wall tympanomastoidectomy
Number of subjects: 12
Study 7818063 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium administered by the Springfusor infusion device
Number of subjects: 20
Study 7818063 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium by intermittent bolus injection
Number of subjects: 20
Study 3247518 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (two 1‐mg capsules)
Number of subjects: 12
Study 3247518 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical capsules)
Number of subjects: 12
Study 31288778 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic plexus block (PPB) with 5 ml of 1% lidocaine
Number of subjects: 245
Study 31288778 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional periprostatic nerve block (PNB) with 5 ml of 1% lidocaine
Number of subjects: 245
Study 31288778 — intervention group
Group type: COMPARATOR
Intervention: Prostate capsule local anesthesia with 22 ml of 1% lidocaine (Control group)
Number of subjects: 245
Study 27171347 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management of well-being (SMW) interventions
Number of subjects: 445
Study 26425886 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2) for 1 week
Number of subjects: 46
Study 26425886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 23317012 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of juar tea (5 cups/day for 4 weeks)
Number of subjects: 20
Study 23317012 — intervention group
Group type: COMPARATOR
Intervention: Consumption of barley tea (polyphenol-poor tea, 5 cups/day for 4 weeks)
Number of subjects: 20
Study 22044856 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) with PI dose escalation
Number of subjects: 183
Study 22044856 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 183
Study 22044856 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM)
Number of subjects: 183
Study 19936408 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple session risk reduction intervention
Number of subjects: 392
Study 19936408 — intervention group
Group type: COMPARATOR
Intervention: Single session risk reduction intervention
Number of subjects: 392
Study 19936408 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (multiple and single session)
Number of subjects: 392
Study 19936408 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive individuals
Number of subjects: 392
Study 16498855 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine hydrochloride, 180 mg
Number of subjects: 66
Study 16498855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 15306005 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast rectal distension at 100 mL min(‐1)
Number of subjects: 14
Study 15306005 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow rectal distension at 10 mL min(‐1)
Number of subjects: 14
Study 15306005 — intervention group
Group type: COMPARATOR
Intervention: Sham distensions
Number of subjects: 14
Study 11296014 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% brimonidine tartrate
Number of subjects: 20
Study 11296014 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 20
Study 11296014 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of brimonidine and timolol
Number of subjects: 20
Study 9032494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen, 2 mg.day‐1
Number of subjects: 66
Study 9032494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 9032494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 66
Study 30354703 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosing of antihypertensive agents
Number of subjects: 103
Study 30354703 — intervention group
Group type: COMPARATOR
Intervention: Evening dosing of antihypertensive agents
Number of subjects: 103
Study 27513534 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C
Number of subjects: 897
Study 27513534 — intervention group
Group type: COMPARATOR
Intervention: Targeted temperature management at 36°C
Number of subjects: 897
Study 27513534 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 897
Study 24245845 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily self-weighing (DSW)
Number of subjects: 178
Study 22203756 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥ 30 kg/m(2))
Number of subjects: 2693
Study 22203756 — intervention group
Group type: EXPERIMENTAL
Intervention: dMMR tumors
Number of subjects: 2693
Study 18650127 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual titration
Number of subjects: 38
Study 18650127 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic titration
Number of subjects: 38
Study 18650127 — intervention group
Group type: COMPARATOR
Intervention: Pressure recommendation by automatic device
Number of subjects: 38
Study 16680954 — intervention group
Group type: EXPERIMENTAL
Intervention: Acticoat (nanocrystalline silver dressing) applied once a day or every other two days depending on wound condition
Number of subjects: 98
Study 16680954 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine (SD-Ag)
Number of subjects: 98
Study 16680954 — intervention group
Group type: EXPERIMENTAL
Intervention: Acticoat (nanocrystalline silver dressing)
Number of subjects: 98
Study 15588342 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir and efavirenz combination therapy
Number of subjects: 0
Study 11841109 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Acupuncture (MA)
Number of subjects: 13
Study 11841109 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS) at 2Hz
Number of subjects: 13
Study 11841109 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS) at 100Hz
Number of subjects: 13
Study 11841109 — intervention group
Group type: COMPARATOR
Intervention: Control (no stimulation)
Number of subjects: 13
Study 9623186 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma lactate concentration
Number of subjects: 200
Study 9623186 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature
Number of subjects: 200
Study 9623186 — intervention group
Group type: EXPERIMENTAL
Intervention: ESR
Number of subjects: 200
Study 9623186 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination combined with standard laboratory tests
Number of subjects: 200
Study 7888703 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal submucosal injection of methotrexate (MXT) 50 mg
Number of subjects: 24
Study 7888703 — intervention group
Group type: COMPARATOR
Intervention: Parenteral injection of methotrexate (MXT) 50 mg
Number of subjects: 24
Study 3209832 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical PGE2 gel application
Number of subjects: 208
Study 3209832 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel application
Number of subjects: 208
Study 31856808 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS-TC
Number of subjects: 2751
Study 31856808 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2751
Study 29016565 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 50000
Study 29016565 — intervention group
Group type: COMPARATOR
Intervention: Annual fecal immunochemical test (FIT)
Number of subjects: 50000
Study 25392187 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 22
Study 25392187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 23169068 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel decompression and single-level fusion
Number of subjects: 207
Study 23169068 — intervention group
Group type: COMPARATOR
Intervention: Multilevel decompression and multilevel fusion
Number of subjects: 207
Study 21992621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-brachial index (ABI), measures of arterial stiffness, postprandial glucose, glycosylated hemoglobin, self-measured blood pressure, presence of comorbidity
Number of subjects: 2688
Study 21992621 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 18 months
Number of subjects: 2688
Study 18326610 — intervention group
Group type: EXPERIMENTAL
Intervention: Early food supplementation
Number of subjects: 2853
Study 18326610 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (MMs)
Number of subjects: 2853
Study 18326610 — intervention group
Group type: COMPARATOR
Intervention: Usual food supplementation
Number of subjects: 2853
Study 18326610 — intervention group
Group type: COMPARATOR
Intervention: 30 mg Fe + 400 microg folate
Number of subjects: 2853
Study 17122221 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg melatonin
Number of subjects: 200
Study 17122221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 14728607 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ/AS
Number of subjects: 472
Study 14728607 — intervention group
Group type: COMPARATOR
Intervention: CQ
Number of subjects: 472
Study 11422888 — intervention group
Group type: EXPERIMENTAL
Intervention: Marathon runners
Number of subjects: 12
Study 9245683 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral smoking cessation treatment plus vigorous exercise
Number of subjects: 281
Study 9245683 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral smoking cessation treatment plus contact control
Number of subjects: 281
Study 8438811 — intervention group
Group type: EXPERIMENTAL
Intervention: ADTP vaccine
Number of subjects: 110
Study 8438811 — intervention group
Group type: COMPARATOR
Intervention: WDTP vaccine
Number of subjects: 110
Study 3125852 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg twice daily
Number of subjects: 52
Study 3125852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 31537090 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 279
Study 31537090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 31062351 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal Angel
Number of subjects: 0
Study 31062351 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotherm X LG
Number of subjects: 0
Study 31062351 — intervention group
Group type: EXPERIMENTAL
Intervention: °M Warmer
Number of subjects: 0
Study 31062351 — intervention group
Group type: EXPERIMENTAL
Intervention: Buddy Lite
Number of subjects: 0
Study 31062351 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 28544230 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac-diabetes self-management program incorporating telephone and text-messaging
Number of subjects: 0
Study 28544230 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 26224790 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial honey
Number of subjects: 371
Study 26224790 — intervention group
Group type: COMPARATOR
Intervention: Control (Nasal mupirocin)
Number of subjects: 371
Study 24355952 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic ice-cream (100 ml)
Number of subjects: 40
Study 24355952 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic curd (100 ml)
Number of subjects: 40
Study 24355952 — intervention group
Group type: COMPARATOR
Intervention: Plain ice-cream (100 ml)
Number of subjects: 40
Study 24355952 — intervention group
Group type: COMPARATOR
Intervention: Plain curd (100 ml)
Number of subjects: 40
Study 22164745 — intervention group
Group type: EXPERIMENTAL
Intervention: ISMN 40 mg
Number of subjects: 156
Study 22164745 — intervention group
Group type: EXPERIMENTAL
Intervention: ISMN ‐ SR 60 mg
Number of subjects: 156
Study 22164745 — intervention group
Group type: COMPARATOR
Intervention: Placebo Vitamin C 100 mg
Number of subjects: 156
Study 22164745 — intervention group
Group type: EXPERIMENTAL
Intervention: ISMN groups (both ISMN 40 mg and ISMN ‐ SR 60 mg)
Number of subjects: 156
Study 19023893 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation training (PERT)
Number of subjects: 19
Study 19023893 — intervention group
Group type: COMPARATOR
Intervention: Strengthening group (STR)
Number of subjects: 19
Study 16686585 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive management from clinical pharmacists and a diabetes care coordinator for 12 months
Number of subjects: 217
Study 16686585 — intervention group
Group type: COMPARATOR
Intervention: Control group attended a single session led by pharmacists, followed by usual care
Number of subjects: 217
Study 16686585 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 217
Study 15656713 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill oil 1-3 g per day (BMI-dependent)
Number of subjects: 120
Study 15656713 — intervention group
Group type: COMPARATOR
Intervention: Fish oil (3 g daily containing 180 mg EPA and 120 mg DHA)
Number of subjects: 120
Study 15656713 — intervention group
Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 120
Study 11355480 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with carcinoma of the larynx
Number of subjects: 7
Study 11355480 — intervention group
Group type: COMPARATOR
Intervention: Healthy persons
Number of subjects: 7
Study 9140154 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (80 mg + mg/h) continuous infusion for 72 hours
Number of subjects: 333
Study 9140154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole
Number of subjects: 333
Study 9140154 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 333
Study 8433137 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-SOD 10,000 U/kg
Number of subjects: 104
Study 8433137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 8433137 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-SOD 5000 U/kg
Number of subjects: 104
Study 8433137 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-SOD 2000 U/kg
Number of subjects: 104
Study 2885354 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 9
Study 31289842 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild Atopic Dermatitis
Number of subjects: 34313
Study 31289842 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe Atopic Dermatitis
Number of subjects: 34313
Study 29357208 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D repletion
Number of subjects: 230
Study 29357208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 24254894 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant thrombomodulin (ART‐123)
Number of subjects: 0
Study 24254894 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 24254894 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with overt DIC
Number of subjects: 0
Study 24784545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention schools (Students for Nutrition and eXercise program)
Number of subjects: 2997
Study 22653986 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (0.3 mg) in exercise group (EX)
Number of subjects: 15
Study 22653986 — intervention group
Group type: COMPARATOR
Intervention: Sublingual nitroglycerin (0.3 mg) in control group (CON)
Number of subjects: 15
Study 22653986 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (0.3 mg) in both groups
Number of subjects: 15
Study 18814887 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid respiratory viral testing on admission
Number of subjects: 204
Study 18814887 — intervention group
Group type: COMPARATOR
Intervention: Routine ED admission protocol
Number of subjects: 204
Study 17329907 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 0
Study 15333311 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week program of vigorous exercises integrated with lectures and discussions on diet, exercise, stress, and smoking
Number of subjects: 442
Study 15333311 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 442
Study 11839888 — intervention group
Group type: EXPERIMENTAL
Intervention: 6932 lead
Number of subjects: 336
Study 11839888 — intervention group
Group type: COMPARATOR
Intervention: 6936 lead
Number of subjects: 336
Study 11839888 — intervention group
Group type: EXPERIMENTAL
Intervention: Both leads
Number of subjects: 336
Study 9845613 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed drainage system and first-generation cephalosporins
Number of subjects: 2755
Study 7854929 — intervention group
Group type: EXPERIMENTAL
Intervention: IMED 980 infusion pump
Number of subjects: 26
Study 7854929 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemini infusion pump
Number of subjects: 26
Study 7854929 — intervention group
Group type: COMPARATOR
Intervention: Gravity flow
Number of subjects: 26
Study 2790405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 20
Study 2790405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1008239 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg of 1,8% dextran in lactated Ringer's solution
Number of subjects: 0
Study 1008239 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane anaesthesia with preanaesthetic volume administration
Number of subjects: 0